---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016231"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:11:35.588932+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Collegium Q3 record revenue $127M (+61% YoY), adj. EPS $1.10, raises FY guidance; completes Xtampza ER renegotiation

## Summary
- Record Q3 revenue $127.0M (+61% YoY); GAAP net income $0.5M ($0.01 EPS), adj. net income $42.5M ($1.10 adj. EPS).
- Completed Xtampza ER contract renegotiations; gross-to-net <65% effective Jan 1, 2023, maintaining broad access.
- Returned $10M capital via share repurchases ($6.4M in Q3, $3.6M in Oct). $42.1M remains under $100M program.
- Updated FY2022 guidance: revenue $455-465M, adj. EBITDA $250-255M, adj. opex $125-130M.
- Ended Q3 with $134.1M cash; made $25M debt repayments; BDSI synergy target raised to ~$85M.

## SEC filing metadata
- accession: 0001558370-22-016231
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/0001558370-22-016231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/coll-20221103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016231
- JSON: https://secwatch.observer/filing/0001558370-22-016231.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016231.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported quarter ended September 30, 2022 results: revenue 127.0 million, net income 0.5 million, EPS 0.01.
  - Period: quarter ended September 30, 2022
  - Revenue: 127.0 million
  - Net income: 0.5 million
  - EPS: 0.01
  - Result: reported results
  source text: Total net product revenues were $127.0 million for the quarter ended September 30, 2022 (the “2022 Quarter”), compared to $78.8 million for the quarter ended September 30, 2021 (the “2021 Quarter”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/0001558370-22-016231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.